Clinical Trials on Stage IIIB Primary Peritoneal Cancer in Spain

Total 790 results

Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, United Kingdom, Austria
Eli Lilly and Company

Completed

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Prostate Cancer

Belgium, Germany, Spain, Poland, Czechia, Hungary, Italy
Sunnybrook Health Sciences Centre
Exact Imaging

Recruiting

Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI (OPTIMUM)

Prostate Cancer

United States, Canada, Austria, France, Germany, Spain, Belgium
Merck Sharp & Dohme LLC
Seagen Inc.; Astellas Pharma Global Development, Inc.

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Urinary Bladder Cancer, Muscle-invasive

Canada, United States, Australia, Belgium, France, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Thailand, Ukraine, Argentina, Colombia, Denmark, Germany, Ireland, Israel, Japan, Malaysia, Philippines, Sing... and more
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb

Active, not recruiting

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

HER2-positive Breast Cancer | HER2-positive Colorectal Cancer | HER2-positive Solid Tumors | HER2-positive Gastroesophageal Cancer | HER2-positive Endometrial Cancer

France, United States, Spain, Korea, Republic of, Italy
AstraZeneca

Completed

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

Breast Cancer | Bone Neoplasms | Prostate Cancer

United States, United Kingdom, Sweden, Norway, Canada, Portugal, Denmark, Spain
European Organisation for Research and Treatment...

Completed

Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer

Endometrial Cancer

Netherlands, France, Spain, United Kingdom, Belgium, Italy, Austria, Portugal
MacroGenics

Terminated

MGC018 With or Without MGA012 in Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Metastatic Castrate Resistant Prostate Cancer | Advanced Solid Tumor, Adult

Spain, United States, Australia, Poland
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Various Advanced Cancer

United States, Czechia, Japan, Poland, Australia, Belgium, Finland, Germany, Italy, Spain, Sweden
Advaxis, Inc.
Gynecologic Oncology Group

Terminated

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer (AIM2CERV)

High Risk Cervical Cancer | Advanced Cervical Cancer

United States, Argentina, Brazil, Canada, Chile, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Serbia, Spain, Taiwan, Ukraine
Genmab

Recruiting

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Squamous Non Small Cell Lung Cancer (NSCLC-SCC) | Breast Cancer, Breast Neoplasms | Endometrial Cancer, Endometrial Neoplasm | Ovarian Cancer, Ovarian Neoplasms

United States, France, Spain, Netherlands, Belgium, United Kingdom, Denmark, Italy, Poland
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
Steba Biotech S.A.

Completed

Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PCM301)

Prostate Cancer

Spain, France, Germany, Netherlands, United Kingdom, Belgium, Finland, Italy, Sweden, Switzerland
Ipsen

Completed

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer (Triptocare)

Prostate Cancer

Spain, Belgium, Netherlands, France, United Kingdom, Denmark, Latvia, Lithuania, Romania, Italy
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Singapore, Australia, France, Germany, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer | VEGF | Solid Tumors and Advanced Endometrial Cancer | Second-line Treatment

Italy, United Kingdom, Spain, Brazil, United States, Korea, Republic of, New Zealand
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
BicycleTx Limited

Recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Head and Neck Cancer | Ovarian Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Solid Tumor Historically Known for High EphA2 Expression | Urothelial Cancer | Gastric/Upper Gastrointestinal Cancer

United States, Belgium, Korea, Republic of, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Breast Cancer | Advanced Solid Tumors | Cowden Syndrome

Netherlands, Spain, Germany, United Kingdom, United States
Mersana Therapeutics
IQVIA Biotech; PSI CRO

Recruiting

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Platinum Resistant Ovarian Cancer | Non Small Cell Lung Cancer Metastatic

United States, Spain, United Kingdom, Australia, France, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hungary, Italy, Lithuania, New Zealand, Norway, Poland, Sweden
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)

Bladder Cancer | Urothelial Carcinoma | Chemotherapy-induced Neutropenia | Myelosuppression Adult | Metastatic Bladder Cancer

Hungary, Spain, United States, France, Georgia
Novartis Pharmaceuticals

Completed

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (TRANSFORM)

Hemodialysis | Renal Replacement Therapy | End Stage Renal Disease (ESRD) | Renal Transplantation | Chronic Kidney Disease (CKD)

Germany, United States, Belgium, Italy, Spain, Croatia, Taiwan, Australia, Austria, Greece, Korea, Republic of, Lebanon, Czechia, Israel, Netherlands, Slovenia, Switzerland, Thailand, Norway, Turkey, Sweden, Argentina, Brazil, Japan, Se... and more
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
HiFiBiO Therapeutics

Recruiting

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Testicular Germ Cell Tumor | Gastric Cancer | Non Small Cell Lung Cancer | Mesothelioma | Head and Neck Squamous Cell Carcinoma

United States, Spain
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Metastatic Renal Cell Carcinoma | Advanced Solid Tumors | Metastatic Breast Cancer

Spain, Belgium, Italy, France, United States, New Zealand, United Kingdom
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Bladder Cancer

United States, France, Belgium, Korea, Republic of, United Kingdom, Czechia, Austria, Canada, Denmark, Greece, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, Poland, Hungary, Switzerland, Japan, Taiwan, Australia, Norway, Germa... and more
Adaptimmune
ICON plc

Recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Melanoma | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Gastric (Stomach) Cancer | Esophagogastric Junction (EGJ) | Non-small Cell Lung (NSCLC)

United States, Canada, Spain, Belgium
Ferring Pharmaceuticals

Completed

A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

Prostate Cancer

Spain, France, Belgium, Italy, Sweden, Portugal, Turkey
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Cervical Cancer

United States, Spain, Japan
AstraZeneca

Completed

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (Capri)

Non-Metastatic Prostate Cancer

Czech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
IO Biotech
Merck Sharp & Dohme LLC; Theradex; Almac; NeoGenomics

Recruiting

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma Bladder | Lung Cancer Non Small Cell

United States, Spain, United Kingdom
AstraZeneca

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5

Canada, China, Spain, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
Bavarian Nordic

Completed

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Prostate Cancer Metastatic

United States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
Ipsen

Active, not recruiting

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate (TriptoSwitch)

Prostate Cancer

Spain, Lithuania, Germany, France, Belgium, Netherlands, Czechia
SOTIO a.s.

Completed

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)

Metastatic Castration-resistant Prostate Cancer

United States, Spain, United Kingdom, Germany, Serbia, Portugal, Lithuania, Slovakia, Hungary, Netherlands, Croatia, France, Czechia, Poland, Austria, Belarus, Belgium, Bulgaria, Denmark, Italy, Latvia, Sweden
Astellas Pharma Inc

Completed

A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD (ICELAND)

Prostate Cancer

Belgium, France, Spain, Italy, Hungary, Russian Federation, Germany, Slovakia, Finland, Czech Republic
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer

Testicular Germ Cell Tumor | Metastatic Cancer | Mediastinal Cancer

United Kingdom, Norway, Switzerland, Spain, Belgium, Netherlands, Germany, Denmark, Slovakia, Italy, Austria, Poland
UNICANCER
Sanofi; European Organisation for Research and Treatment of Cancer - EORTC; I... and other collaborators

Active, not recruiting

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer (PEACE1)

Metastatic Prostate Cancer

France, Ireland, Spain, Switzerland, Belgium, Italy, Romania
Amgen

Completed

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (BONAFIDE)

Secondary Hyperparathyroidism

United States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
Ferring Pharmaceuticals

Completed

Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

Prostate Cancer

Spain, Netherlands, Belgium, Italy, France, Germany
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
Abbott
Massachusetts General Hospital; Harvard University

Terminated

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 (PRIMO II)

Hypertrophy, Left Ventricular | Chronic Kidney Disease (CKD) Stage 5

Italy, United States, Taiwan, Poland, United Kingdom, Greece, Germany, Russian Federation, Spain, Australia, Czech Republic, Puerto Rico, Romania

Clinical Trials on Stage IIIB Primary Peritoneal Cancer in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations